Anti-diabetes oral pharmaceutical composition

An anti-diabetic and composition technology, which is applied in the field of anti-diabetic oral pharmaceutical composition, can solve problems such as rising drug costs, increased treatment costs, and health damage

Inactive Publication Date: 2016-02-03
朱忠良
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the side effects of active substances, other health damages have been caused to patients. At the same time,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-diabetes oral pharmaceutical composition
  • Anti-diabetes oral pharmaceutical composition
  • Anti-diabetes oral pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] I. 5-(3-Hydroxy-7-propoxynaphthalen-2-yl)-1,1-dioxo-[1,2,5]thiadiazolidin-3-one potassium salt

[0019]

[0020] step 1

[0021] 3-Hydroxy-7-propoxynaphthalene-2-propyl carboxylate

[0022] To a suspension of 1.6 g (29.6 mmol) sodium methoxide in DMA (30 mL) was added 3.0 g (14.7 mmol) 3,7-dihydroxynaphthalene-2-carboxylic acid. The mixture was stirred at room temperature for 1 hour, then 5.05 g (29.7 mmol) of propyl iodide were added and stirring was continued for 48 hours. The mixture was poured into water and acidified with 2N HCl. The mixture was extracted with ethyl acetate and the organic phase was washed with water (3x) and brine (1x). The solution was dried over sodium sulfate and the solvent was removed under reduced pressure. The residual oil was purified by flash chromatography with dichloromethane, eluting the title compound, which was isolated as a yellow oil. MS (M-1): 287.

[0023] step 2

[0024] 3-Benzyloxy-7-propoxynaphthalene-2-propyl carbox...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an anti-diabetes oral pharmaceutical composition, which comprises the following components: 1) 10-20 mg of 5-(3-hydroxy-7-propoxynaphthalene-2-yl)-1,1-dioxo-[1,2,5]thiadiazolidine-3-ketone potassium salt, 2) 20-30 mg of 3-(2-(2',6'-dimethyl-[1,1'-biphenyl]-3-yl)chroman)-6-yl) hexanenitrile-4-acetylenic acid, 3) 200-300 mg of microcrystalline cellulose, 4) 10-25 mg of cross linked sodium carboxymethyl cellulose, and 5) 1-8 mg of magnesium stearate. By complex formulation of two different types of active matters, under prerequisite that treatment effect is same, the application amount of the active matter of the medicine is reduced by at least 1/2.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to an antidiabetic oral pharmaceutical composition. Background technique [0002] Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia is caused by defective insulin secretion or impaired biological action, or both. The long-term high blood sugar in diabetes leads to chronic damage and dysfunction of various tissues, especially the eyes, kidneys, heart, blood vessels, and nerves. [0003] There are generally two recognized forms of diabetes. In type 1 diabetes, or insulin-dependent diabetes mellitus (IDDM), patients produce little or no insulin, the hormone that regulates glucose utilization. In type 2 diabetes, or non-insulin-dependent diabetes mellitus (NIDDM), insulin is still produced in the body. Patients with type 2 diabetes are resistant to the action of insulin in stimulating glucose and lipid metabolism in the main insulin sensitive t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/433A61P3/10A61K31/353
Inventor 朱忠良
Owner 朱忠良
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap